MHRA touts uptick in approvals in 2025-2026 annual report

20 Jul 2026 Study: China outpaces the US in cancer approvals, lags behind on first approvals While China's National Medical Products Administration (NMPA) approved more oncology drugs compared to the US Food and Drug Administration (FDA) from 2020 to 2025, the US regulator approved more first-in-class drugs and tended to approved products faster and earlier than China, according to a recent study published in Health Affairs. Regulatory News